Novo Nordisk announced on its official website the primary results of a Phase 2a clinical trial for its investigational drug monlunabant (previously known as INV-202).

Accent Therapeutics has received FDA approval for its IND application for ATX-559, the first oral inhibitor targeting DHX9.

Sanofi announced its entry into the nuclear medicine field through an exclusive licensing agreement with RadioMedix and Orano Med to jointly develop next-generation RLT for rare cancers.

Tyra Biosciences has shared preliminary clinical proof-of-concept findings for TYRA-300, a selective oral FGFR3 inhibitor.

Schrödinger shared new preclinical findings on SGR-3515 during a poster session at the 36th EORTC-NCI-AACR Symposium (ENA 2024).

The European Commission has approved a quadruplet treatment regimen using DARZALEX® (daratumumab)-SC for newly diagnosed multiple myeloma patients eligible for transplantation.

Under this agreement, TerSera will obtain the worldwide rights to MARGENZA® (margetuximab-cmkb).

Otsuka Reports Encouraging Interim Findings from Phase 3 Study of Sibeprenlimab for Treating IgA Nephropathy in Adults.

Nurix Therapeutics announces encouraging findings from the ongoing clinical study of its BTK degrader NX-5948 in patients with relapsed/refractory Waldenström’s macroglobulinemia.

Zymeworks has reported that the initial patient has been dosed in a Phase 1 clinical trial assessing ZW171 for advanced cancers that express mesothelin.

REGENXBIO shares favorable results from the Phase II trial of subretinal ABBV-RGX-314 for bilateral wet AMD patients at AAO 2024.

Adcentrx Therapeutics has received FDA approval for its Investigational New Drug application for ADRX-0405, a promising first-in-class ADC aimed at STEAP1.